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Sstudy may be the major reason for smaller infarction size, which might translate to
a better long-term prognosis. Expansion of sample size may help to get more
persuasive conclusion.
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Background: To date, endovascular reperfusion is the essential method for the
treatment of AMI, however it has some negative aspects, such as reperfusion injury of
the myocardium, distal embolism, etc. Intracoronary administration of drugs provides
their fast transport to the target organ and can play a decisive role in the improvement
of the results of treatment of AMI.
Methods: The study comprised 253 patients (average age - 567 years) with acute
occlusion of the proximal or middle segment of the LAD and absent antegrade blood
ﬂow (TIMI 0), who underwent successful recanalization of IRA within the ﬁrst 6
hours after the onset of AMI. Prior to angiography, all patients were randomized into 2
groups. Patients from Group I (n¼126) received intracoronary Mexicor (0,2 g).
Patients from Group II (control, n¼127) did not receive. Intracoronary administration
was performed through a special microcatheter during 10 min. Blood samples for
markers of cardiomyocytes injury (Troponin I, myoglobin) were taken during
recanalization of IRA, in 12 and 24 hours after the procedure.
Results: In-hospital course of the disease was rather uneventful, 1 patient (0,8%) died
in Gr. I and 3 (2,3%) – in Gr. II. Average values of Troponin I at 12 hours after the
procedure in Grs. I and II were 31147 and 63239 ng/ml, respectively (p<0,05). In
the long-term after the procedure, in average – in 6,80,7 months, the survival in Gr. I
was 96,8%, in Gr. II - 87,6% (p>0,05). Baseline clinical indices in both groups were
not signiﬁcantly different. The increase of LV EF in Grs. I and II was 9,25,1% and
4,18,2%, respectively (p<0,05). We also noted a signiﬁcantly better dynamics of
contractility on infarct-related segments of the LV in Gr.I in comparison with Gr. II
(p<0,05) (table 1).
Conclusions: Our study suggests that intracoronary administration of metabolic
cytoprotector Mexicor Upoin accordance with a special technique limits reperfusion
injury of the myocardium and contributes to the preservation of structural and func-
tional integrity of cardiomyocytes after antegrade blood ﬂow restoration in IRA within
the ﬁrst hours after the onset of AMI.
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Background: Rapid time to reperfusion in STEMI is required to maximize
myocardial salvage. Conversely, reperfusion success is diminished in patients pre-
senting late. In the randomized MASTER trial, the MGuard Embolic Protection Stent
was shown to improve TIMI-3 ﬂow and ST-segment resolution (STR) compared to
control DES or BMS. We thus sought to evaluate the impact of symptom onset to
balloon time on the efﬁcacy of this novel device.
Methods: The MGuard is a novel thin-strut metallic embolic protection stent with
a PET micronet covering designed to trap and exclude thrombus and friable athero-
matous debris and prevent distal embolization. A total of 433 patients with STEMI
<12 hours in duration undergoing PCI were randomized to either the MGuard stent
vs. a control (BMS or DES) stent.
Results: Symptom onset to balloon time was <180 minutes in 157 pts, and 180
minutes in 253 pts. Pts reperfused early vs. late were more likely to achieve complete
STR (58.6% versus 47.0%, P¼0.02), and had more rapid cTFC (15.0 vs. 18.0 frames,
p¼0.005). In the entire patient cohort, complete STR and TIMI-3 ﬂow were signiﬁ-
cantly improved with the MGuard stent compared to control stents (57.8% vs. 44.7%,
P¼0.008; and 91.7% vs. 82.9%, p¼0.006, respectively). The results of
stent randomization according to symptom onset to balloon time (SBT) appear in the
table.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Compared to standard stents, the MGuard Embolic Protection Stent
improves reperfusion success in both patients with rapid and delayed time to reper-
fusion, although the absolute magnitude of beneﬁt may be greater in patients with
delays from symptom onset to reperfusion.
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Background: Longer delay from symptom onset to reperfusion has been linked to
increased mortality and worse clinical outcome. The mechanism underpinning this
association is not entirely clear. Thus, we evaluated the impact of the delay from
symptom onset to reperfusion(<3 vs. 3 h) on infarct size and clinical outcomes at 30
days and 1 year in patients with STEMI) treated with primary PCI.
Methods: The INFUSE-AMI trial randomized patients with anterior STEMI under-
going primary PCI with bivalirudin anticoagulation to intralesion (IL) bolus abcix-
imab vs. no abciximab, and to thrombus aspiration vs. no aspiration. The primary
endpoint was cMRI infarct size (IS, % of left ventricular mass) at 30 days. Time to
reperfusion was classiﬁed as <3 vs. 3 h.
Results: There were 280 (62%) patients with <3h delay and 170 (38%) with 3h
delay. Patients with longer delay were signiﬁcantly older, more often women and
diabetics. IS was marginally smaller in patients with shorter delay to reperfusion
(16.4% [6.5, 22.9] vs. 18.1% [10.5, 24.8], respectively, P¼0.07). However, shorter
delay to reperfusion was not associated with higher rates of ﬁnal TIMI 3 ﬂow or
myocardial blush grade 2/3. There was signiﬁcantly lower mortality and morbidity at
30 days and at 1 y in patients with shorter delay (Figure). Delay 3h was an inde-
pendent predictor of 1-year MACCE, but not of death or MACE.
Conclusions: Even with contemporary primary PCI, longer delay to reperfusion
negatively impacts clinical outcome. This effect appears not to be mediated by less
successful reperfusion or by a markedly larger infarct size.TCT-231
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Background: Patients with a history of CABG have traditionally been excluded from
randomized studies comparing PCI and CABG. The optimal revascularization strategy
in these patients is not well deﬁned. We therefore sought to evaluate the relationship
between revascularization strategy and outcomes in patients with prior CABGacts/POSTER/STEMI/NSTEMI/ACS B75
